 The prevalence of PPI use in the UK general population is high and still increasing.
INTRODUCTION

20
The introduction of proton pump inhibitors (PPIs) has revolutionised the management of 21 acid-related gastrointestinal disorders 1 . In the United Kingdom (UK), 11,126 thousand 22 prescriptions for PPIs were dispensed in 2000 2 , and this increased to 43,127 thousand in 23 2011 3 . Although the expenditure on PPIs has decreased in the UK since 2006 as a result of 24 government efforts to encourage the use of low-cost generic PPIs 4, 5 , there has still been an 25 overall increase in the total number of PPI prescriptions dispensed 4 . For instance, in 2010, 26 PPIs became one of the top 20 drugs with the greatest net ingredient cost in the UK 4 .
27
The importance of reducing any overuse of PPIs is not limited to the associated costs, but 28 also to the risks of taking the drugs on a long-term basis 6 . As PPIs have become commonly 29 used for long-term maintenance, concerns have been raised about the safety of such use 6 . 30 Studies have showed that PPI use is associated with malabsorption of vitamins and 31 minerals 7, 8 , an increased risk of infections, such as pneumonia 9 and enteric infection 10 , and 32 an increased fracture risk 11, 12 . These potential side effects can be minimized through 33 appropriate prescription practices in terms of stepping down the dose or stopping long-term 34 treatment altogether. 35 As a consequence of this dramatic increase in PPI use and the associated potential risks, 36 clinical guidelines in the UK have recommended rationing the use of the PPI in the primary 37 care setting, either by stepping down the dose or stopping treatment all together 13 . 38 However, very few research studies have examined the extent to which the clinical guidelines 39 are being followed in the UK [14] [15] [16] [17] [18] [19] . The aim of this study was to determine the prevalence of 40 PPI use and assess the practices employed to reduce PPI use in the general UK population. It 41 is anticipated that research of this nature will help to inform future attempts to moderate the 42 use of PPIs.
43
METHODS
44
Study type and data source 45 We conducted an observational study with repeated cross-sectional analyses to estimate the 46 prevalence of PPI use annually and a cohort design to describe the patterns of PPI utilization 47 by using data from the UK Clinical Practice Research Datalink (CPRD) 20 . CPRD is a large 48 database drawn from the computerised records of primary care practices throughout the UK 49 and encompassing a representative sample of around 6% of UK population [21] [22] [23] 21, 24 .
55
Study population
56
We studied adult patients with at least one month of prospective records after either the 57 date of their current registration or the date after the practice became "up to standard" 58 (UTS) on CPRD 21 whichever was the latest, and an "acceptable" registration status as defined 59 by CPRD 21 between 1st Jan 1990 and 31st December 2014. This population formed our 60 denominator for studies of prevalence. Patients who received ≥1 PPI prescription(BNF 1.3.5 61 25 ) were classified as exposed subjects in the study (i.e. the numerator).
62
Prescription duration
63
The earliest PPI prescription for each patient was considered their index date. Prescription 64 duration was taken as the number of treatment days recorded by the GP, or calculated from 65 the prescribed quantity and numeric daily dose prescribed. If information on both was 66 missing, the individual median duration was imputed. The duration was recalculated if the 67 calculated prescription duration was less than or equal to seven days assuming that the 68 prescription quantity was referring to the number of individual product packs prescribed. Lastly, a switch to H2RA medication was defined as receiving H2RA prescription within one 97 month before or after discontinuation or stepping down attempt.
98
Covariates
99
We abstracted data on patients' age at the index date (in 10-year age bands), gender, and 
115
Patterns of PPI use
116
The baseline patient characteristics and the use of PPIs among new users were described as 117 proportions of age bands, genders and quintiles of IMD (to represent socioeconomic status).
118
We calculated the percentage of patients who continued their first PPI course, from the index 119 date to the end of five years of follow-up during the study period. prophylaxis or reducing the degradation of pancreatic enzyme supplements were excluded.
137
Analyses were performed using STATA 12 (Stata Corp, College Station, Texas).
138
RESULTS
139
Prevalence of prescribing Figure 2 shows the proportion of patients who discontinued the first PPI course (Figure 2-A) , 172 and patients who permanently discontinued all PPI courses (Figure 2-B) . When considering 173 only long-term PPI patients, 25% had temporarily discontinued their therapy at one year and 174 three months after starting their long-term PPI course, 50% at one year and seven months 175 and by two years and three months 75% had temporarily discontinued their long term PPI 176 course. Of those discontinuing, 9,557 (9%) received a prescription for H2RA within one 177 month before or after this occurred.
178
Of the 159,259 patients who received long term PPIs, 63,640 (39.9%) had an attempt to 179 step down their PPI dose (Table3). Of these 6,388 (10%) had received an H2RA prescription 180 within one month before or after stepping down PPI dose.
181
Of 59,734 patients in whom the initial indication for PPI prescription did not suggest a 182 recognised need for PPI use to be prolonged, un-complicated GORD was the most frequent 
208
In this study, the proportion of patients who were on long-term PPI (26%) was higher 209 than that reported in previous studies [16] [17] [18] 34 . The issue of appropriateness in terms of prescription practices has been discussed 229 in existing literature 29, 35, 36 . Despite this, PPIs are still being administered to patients for a 230 variety of complaints that are not known to be acid-induced and over a long-term basis.
231
In the view of the emerging concerns regarding adverse events from long-term PPI 232 use, clinical guidelines 13 have encouraged GPs to use PPIs carefully and to continually review medication. Previous studies [36] [37] [38] [39] reported discontinuation rates that differed from those 236 identified in our study; however, these can be explained by variations in the study population 237 and the discontinuation strategies employed 38 . Reports regarding the outcomes of step-238 down therapy have been conflicting 40, 41 . For example, one study reported that more than 239 half of the patients involved in the study remained asymptomatic after the step down 41 while 240 another reported that 19% of patients whose PPI therapy was stepped down experienced 241 relapsed symptoms and resumed PPI use 40 . In our study, 60% of the long-term PPI users 242 maintained lower doses for more than one year. However, while we identified an appreciable 243 proportion of long-term PPI users who could potentially reduce the use of the drug, we were 244 unable to find evidence of such attempts in a large proportion of those individuals. Non-245 adherence to the step down therapy, therefore, allows the maintenance of inappropriate PPI 246 prescription which may sustains overuse of PPIs.
247
Strengths and limitations
248
Our study used data from a large database of UK primary care records which has been 249 extensively used and validated for pharmacoepidemiological research 21, 24 . The population in 250 our study is therefore representative of the general practice population of the UK to whom 251 our results should be generalizable 21 . The large sample size has allowed us to stratify our Weaknesses in our study include that we may have underestimated PPI use since neither 256 hospital prescriptions nor over the counter (OTC) use are captured in the data. However, 257 since secondary care initiated PPI treatment will often be continued by GPs afterwards 35 , and 258 prescribed PPI use continued to rise after they became available OTC 42 we think it unlikely 259 that this has led to massive underestimation. Additionally, we focused on long-term users 260 who would be the most likely to obtain their prescriptions from their GPs. Furthermore, the adherence to the guidelines is likely to be required.
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